Cure Pharmaceutical navigates CBD acquisition, licensing dispute

You are here: Home > Banking & Finance > Current Article

Cure Pharmaceutical navigates CBD acquisition, licensing dispute

By Jorge Mercado / Friday, April 9th, 2021 / Comments Off on Cure Pharmaceutical navigates CBD acquisition, licensing dispute

Oxnard-based Cure Pharmaceutical saw big rise in revenue in the fourth quarter of 2020 as it integrates a major acquisition, but growing net losses and a dispute with a licensee could be obstacles going forward. Cure closed the acquisition of the CBD company Sera Labs on Oct. 2, according to Cure’s 2020 annual report, filed…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.